Cargando…

Epigenetic modification and BRAF gene mutation in thyroid carcinoma

Thyroid cancer remains the most prevailing endocrine malignancy, and a progressively increasing incidence rate has been observed in recent years, with 95% of thyroid cancer represented by differentiated thyroid carcinomas. The genetics and epigenetics of thyroid cancer are gradually increasing, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Guo, Chen, Juan, Zhou, Jun, Xiao, Shuai, Zeng, Weihong, Xia, Jiliang, Zeng, Xi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684614/
https://www.ncbi.nlm.nih.gov/pubmed/34923978
http://dx.doi.org/10.1186/s12935-021-02405-w
_version_ 1784617654147874816
author Huang, Guo
Chen, Juan
Zhou, Jun
Xiao, Shuai
Zeng, Weihong
Xia, Jiliang
Zeng, Xi
author_facet Huang, Guo
Chen, Juan
Zhou, Jun
Xiao, Shuai
Zeng, Weihong
Xia, Jiliang
Zeng, Xi
author_sort Huang, Guo
collection PubMed
description Thyroid cancer remains the most prevailing endocrine malignancy, and a progressively increasing incidence rate has been observed in recent years, with 95% of thyroid cancer represented by differentiated thyroid carcinomas. The genetics and epigenetics of thyroid cancer are gradually increasing, and gene mutations and methylation changes play an important roles in its occurrence and development. Although the role of RAS and BRAF mutations in thyroid cancer have been partially clarified,but the pathogenesis and molecular mechanisms of thyroid cancer remain to be elucidated. Epigenetic modification refer to genetic modification that does not change the DNA sequence of a gene but causes heritable phenotypic changes in its expression. Epigenetic modification mainly includes four aspects: DNA methylation, chromatin remodelling, noncoding RNA regulation, and histone modification. This article reviews the importance of thyroid cancer epigenetic modification and BRAF gene mutation in the treatment of thyroid cancer.
format Online
Article
Text
id pubmed-8684614
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-86846142021-12-20 Epigenetic modification and BRAF gene mutation in thyroid carcinoma Huang, Guo Chen, Juan Zhou, Jun Xiao, Shuai Zeng, Weihong Xia, Jiliang Zeng, Xi Cancer Cell Int Review Thyroid cancer remains the most prevailing endocrine malignancy, and a progressively increasing incidence rate has been observed in recent years, with 95% of thyroid cancer represented by differentiated thyroid carcinomas. The genetics and epigenetics of thyroid cancer are gradually increasing, and gene mutations and methylation changes play an important roles in its occurrence and development. Although the role of RAS and BRAF mutations in thyroid cancer have been partially clarified,but the pathogenesis and molecular mechanisms of thyroid cancer remain to be elucidated. Epigenetic modification refer to genetic modification that does not change the DNA sequence of a gene but causes heritable phenotypic changes in its expression. Epigenetic modification mainly includes four aspects: DNA methylation, chromatin remodelling, noncoding RNA regulation, and histone modification. This article reviews the importance of thyroid cancer epigenetic modification and BRAF gene mutation in the treatment of thyroid cancer. BioMed Central 2021-12-19 /pmc/articles/PMC8684614/ /pubmed/34923978 http://dx.doi.org/10.1186/s12935-021-02405-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Huang, Guo
Chen, Juan
Zhou, Jun
Xiao, Shuai
Zeng, Weihong
Xia, Jiliang
Zeng, Xi
Epigenetic modification and BRAF gene mutation in thyroid carcinoma
title Epigenetic modification and BRAF gene mutation in thyroid carcinoma
title_full Epigenetic modification and BRAF gene mutation in thyroid carcinoma
title_fullStr Epigenetic modification and BRAF gene mutation in thyroid carcinoma
title_full_unstemmed Epigenetic modification and BRAF gene mutation in thyroid carcinoma
title_short Epigenetic modification and BRAF gene mutation in thyroid carcinoma
title_sort epigenetic modification and braf gene mutation in thyroid carcinoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684614/
https://www.ncbi.nlm.nih.gov/pubmed/34923978
http://dx.doi.org/10.1186/s12935-021-02405-w
work_keys_str_mv AT huangguo epigeneticmodificationandbrafgenemutationinthyroidcarcinoma
AT chenjuan epigeneticmodificationandbrafgenemutationinthyroidcarcinoma
AT zhoujun epigeneticmodificationandbrafgenemutationinthyroidcarcinoma
AT xiaoshuai epigeneticmodificationandbrafgenemutationinthyroidcarcinoma
AT zengweihong epigeneticmodificationandbrafgenemutationinthyroidcarcinoma
AT xiajiliang epigeneticmodificationandbrafgenemutationinthyroidcarcinoma
AT zengxi epigeneticmodificationandbrafgenemutationinthyroidcarcinoma